Jennifer Barrett, Associate Editor

A new study has found that arthritis is commonly reported in older adults with varying degrees of depression, highlighting the importance of screening and treating arthritis-related pain in these patients.

Study highlights mechanism of endocrine resistance in estrogen receptor-positive breast cancers and potential therapeutic targets.

The study points to the importance of screening for and treating arthritis-related pain in older adults with varying degrees of depression.

Inotersen (Tegsedi) once-weekly subcutaneous injection is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis.

Survey data reveal rates of diabetes prevalence by subtype among adults.

Clinical trial data show results from switching to Delstrigo from other antiretroviral treatments for HIV.

Emicizumab-kxwh (Hemlibra) is now the only prophylactic treatment approved for individuals with hemophilia A with and without factor VIII inhibitors.

Officials with the FDA have approved emicizumab-kxwh (Hemlibra, Genentech) for routine prophylaxis to prevent or reduce frequency of bleeding episodes in adults and children, ages newborn and older, with hemophilia A without factor VIII inhibitors.

Emicizumab-kxwh (Hemlibra) is now the only FDA-approved treatment for hemophilia A with and without factor VIII inhibitors.

A combination of 2 anti-HIV antibodies may be capable of suppressing HIV for months after treatment.

Artificial intelligence tool can analyze images of patients’ lung tumors, specify cancer types, and identify altered genes driving abnormal cell growth.

Study examines the role of liver macrophages as a long-lived HIV-1 cellular reservoir.

Based on evidence from a systematic review, researchers are calling for increased access to lifesaving hepatitis C treatments for injection drug users.

Latest approval for carfilzomib offers a more convenient dosing option for patients with multiple myeloma.

Lymphatic vessels surrounding the brain may play a key role in the development and progression of multiple sclerosis.

Dacomitinib tablets (Vizimpro, Pfizer) received FDA approval for the first-line treatment of patients with metastatic non-small cell lung cancer.

The FDA has approved Eli Lilly’s preventive migraine treatment galcanezumab-gnlm (Emgality).

Entrectinib showed a durable response and reduced tumors in patients with ROS1-positive non-small cell lung cancer.

The US Preventive Services Task Force recommends against routine screening for prostate cancer in men 70 years of age and older.

A mobile app technology used to identify and track symptom relief helped measure real-time cannabis use.

A national survey demonstrated gaps in medical providers’ knowledge about changes to HIV health care delivery due to the Affordable Care Act.

In 2016, 5 million deaths in low- and middle-income countries (LMICs) were estimated to be due to poor-quality health care.

Phase 3 trial results for dupilumab (Dupixent) demonstrate improvement in skin clearing, itch, and certain quality of life measurements for adolescents with atopic dermatitis.

The phase 3 PARADIGMS clinical trial is the first-ever study designed for children and adolescents aged 10 to 17 years old with relapsing forms of multiple sclerosis.

Implementation of universal health care is part of the Sustainable Development Goals (SDGs), which are new targets signed by 193 United Nations member states to improve health and development by 2030.

Deaths due to poor-quality health care represent a substantial challenge for universal coverage in low- and middle-income countries.

Sequential administration of HER2+ therapy and chemotherapy did not affect survival outcomes in patients with breast cancer.

Almirall has received European Commission approval for its plaque psoriasis treatment tildrakizumab (Ilumetri).

The National Comprehensive Cancer Network updated its Clinical Practice Guidelines for kidney cancer to include new recommendations for cabozantinib tablets.

When used in combination with an anti-PD-L1 therapy, a novel vaccine plus Diprovocim increased survival in mice with melanoma.